2018
Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing
Giri V, Hegarty S, Hyatt C, O'Leary E, Garcia J, Knudsen K, Kelly W, Gomella L. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. The Prostate 2018, 79: 333-339. PMID: 30450585, DOI: 10.1002/pros.23739.Peer-Reviewed Original ResearchConceptsBreast cancer family historyCancer family historyProstate cancerFamily historyMetastatic diseaseGleason scoreExact testGenetic testingRetrospective cross-sectional analysisDNA repair genesCurrent NCCN guidelinesInherited prostate cancerGermline genetic testingHigh Gleason scoreFisher's exact testIdentification of menRepair genesPathogenic variant spectrumCross-sectional analysisFamily history dataGenetic testing capabilitiesNCCN guidelinesTherapeutic managementMultigene testingPV rates
2015
High prevalence of discordant human papillomavirus and p16 oropharyngeal squamous cell carcinomas in an African American cohort
Liu J, Parajuli S, Blackman E, Gibbs D, Ellis A, Hull A, Beck J, Giri V, Iherjirka P, Khurana J, Ragin C. High prevalence of discordant human papillomavirus and p16 oropharyngeal squamous cell carcinomas in an African American cohort. Head & Neck 2015, 38: e867-e872. PMID: 25962720, PMCID: PMC4643423, DOI: 10.1002/hed.24117.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell carcinomaSquamous cell carcinomaAfrican American cohortPolymerase chain reactionAmerican cohortHPV- oropharyngeal squamous cell carcinomaHPV/p16 statusIncidence of HPVAfrican American patientsTumor RegistryCell carcinomaSCC cohortHuman papillomavirusP16 statusAmerican patientsP16 stainingTumor blocksHPVPatientsStandard immunohistochemistryTumor typesP16 negativityCohortChain reactionSurvival
2007
Prostate Cancer Risk Assessment Program: A 10-Year Update of Cancer Detection
Giri V, Beebe-Dimmer J, Buyyounouski M, Konski A, Feigenberg S, Uzzo R, Hanks G, Godwin A, Chen D, Gordon R, Cescon T, Raysor S, Watkins-Bruner D. Prostate Cancer Risk Assessment Program: A 10-Year Update of Cancer Detection. Journal Of Urology 2007, 178: 1920-1924. PMID: 17868726, DOI: 10.1016/j.juro.2007.07.010.Peer-Reviewed Original ResearchConceptsProstate Cancer Risk Assessment ProgramCancer Risk Assessment ProgramProstate-specific antigenProstate cancerSpecific antigenHigh riskRisk assessment programFamily historyNormal digital rectal examinationFree prostate-specific antigenLongitudinal screening programUnderwent prostate biopsyDigital rectal examinationProstate cancer incidenceGleason score 7Prostate cancer featuresGleason score 6Majority of cancersCancer detectionParticipants 19Biopsy criteriaLocal therapyRectal examinationProstate biopsyCancer incidence
2005
Causes of Preventable Visual Loss in Type 2 Diabetes Mellitus
Hayward R, Cowan C, Giri V, Lawrence M, Makki F. Causes of Preventable Visual Loss in Type 2 Diabetes Mellitus. Journal Of General Internal Medicine 2005, 20: 467-469. PMID: 15963174, PMCID: PMC1490102, DOI: 10.1111/j.1525-1497.2005.40073.x.Peer-Reviewed Original ResearchConceptsAnnual retinal examinationPreventable visual lossLarge referral centerThird of casesPercent of casesRetinal examinationReferral centerVisual lossDiabetic retinopathyMedical recordsWasteful careRetinal photocoagulationType 2PatientsPhotocoagulationSuboptimal timingCurrent performance measuresThirdMellitusRetinopathyVisitsCareMonths